[go: up one dir, main page]

WO2019203752A3 - Combinations comprising a skeletal muscle relaxant agent and a multiple sclerosis treating agent - Google Patents

Combinations comprising a skeletal muscle relaxant agent and a multiple sclerosis treating agent Download PDF

Info

Publication number
WO2019203752A3
WO2019203752A3 PCT/TR2018/050800 TR2018050800W WO2019203752A3 WO 2019203752 A3 WO2019203752 A3 WO 2019203752A3 TR 2018050800 W TR2018050800 W TR 2018050800W WO 2019203752 A3 WO2019203752 A3 WO 2019203752A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
combinations
multiple sclerosis
skeletal muscle
muscle relaxant
Prior art date
Application number
PCT/TR2018/050800
Other languages
French (fr)
Other versions
WO2019203752A2 (en
Inventor
Ali TÜRKYILMAZ
Nur PEHLIVAN AKALIN
Arzu Palantöken
Sibel ZENGINER
Merve PEKER
Emine TUNCAY
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to EP18915063.4A priority Critical patent/EP3723755A4/en
Publication of WO2019203752A2 publication Critical patent/WO2019203752A2/en
Publication of WO2019203752A3 publication Critical patent/WO2019203752A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to combinations which comprise at least one skeletal muscle relaxant agent and at least one multiple sclerosis treating agent.
PCT/TR2018/050800 2017-12-14 2018-12-12 Combinations comprising a skeletal muscle relaxant agent and a multiple sclerosis treating agent WO2019203752A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP18915063.4A EP3723755A4 (en) 2017-12-14 2018-12-12 Combinations comprising a skeletal muscle relaxant agent and a multiple sclerosis treating agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/20406 2017-12-14
TR2017/20406A TR201720406A2 (en) 2017-12-14 2017-12-14 COMBINATIONS CONTAINING A SKELETAL MUSCLE LOAER AND A MULTIPLE SCLEROSIS THERAPY

Publications (2)

Publication Number Publication Date
WO2019203752A2 WO2019203752A2 (en) 2019-10-24
WO2019203752A3 true WO2019203752A3 (en) 2020-01-16

Family

ID=67900478

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/050800 WO2019203752A2 (en) 2017-12-14 2018-12-12 Combinations comprising a skeletal muscle relaxant agent and a multiple sclerosis treating agent

Country Status (3)

Country Link
EP (1) EP3723755A4 (en)
TR (1) TR201720406A2 (en)
WO (1) WO2019203752A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201818859A2 (en) * 2018-12-07 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A combination comprising dimethyl fumarate and at least one muscle relaxant agent
TR201819202A2 (en) * 2018-12-12 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A COMBINATION CONTAINING ONE MULTIPLE SCLEROSIS AGENT AND AT LEAST ONE MUSCLE RELAXING AGENT
TR201820976A2 (en) * 2018-12-28 2020-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi PHARMACEUTICAL COMBINATIONS WITH FINGOLIMOD AND A SPASMOLITHIC
JP7503420B2 (en) * 2020-05-18 2024-06-20 東和薬品株式会社 Pharmaceutical composition containing fingolimod, and its manufacturing method and stabilization method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073510A1 (en) * 2014-11-04 2016-05-12 Adamas Pharmaceuticals, Inc. Methods of administering amantadine compositions
WO2017031276A1 (en) * 2015-08-19 2017-02-23 The Regents Of The University Of California Methods of providing neuroprotective therapy related to administering an estrogen receptor beta ligand

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073510A1 (en) * 2014-11-04 2016-05-12 Adamas Pharmaceuticals, Inc. Methods of administering amantadine compositions
WO2017031276A1 (en) * 2015-08-19 2017-02-23 The Regents Of The University Of California Methods of providing neuroprotective therapy related to administering an estrogen receptor beta ligand

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OTERO-ROMERO, S. ET AL.: "Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper", MULTIPLE SCLEROSIS JOURNAL, vol. 22, no. 11, pages 1386 - 1396 *

Also Published As

Publication number Publication date
WO2019203752A2 (en) 2019-10-24
TR201720406A2 (en) 2019-07-22
EP3723755A4 (en) 2021-09-15
EP3723755A2 (en) 2020-10-21

Similar Documents

Publication Publication Date Title
EP4470613A3 (en) Pth prodrugs
WO2017136450A3 (en) Compounds and methods of treating rna-mediated diseases
WO2019203752A3 (en) Combinations comprising a skeletal muscle relaxant agent and a multiple sclerosis treating agent
EP3654982A4 (en) 1,8-naphthyridinone compounds and uses thereof
GB201900665D0 (en) 06557607002
WO2016167944A8 (en) Compositions and methods for treating autism
WO2017120527A3 (en) Therapeutic compositions and methods for treating hepatitis b
PL4073029T3 (en) Trisamide compounds and compositions comprising the same
PL4073164T3 (en) Trisamide compounds and compositions comprising the same
WO2017127706A8 (en) Compositions and methods for inhibiting dkk-1
GB202015822D0 (en) 66.123.142648/01
WO2019203755A3 (en) A solid oral dosage form comprising linagliptin
EP3864105A4 (en) Compositions comprising 2,3,3,3-tetrafluoropropene
WO2020122839A3 (en) A combination comprising a multiple sclerosis agent and at least one muscle relaxant agent
WO2017011637A3 (en) Mechanically flexible interconnects, methods of making the same, and methods of use
GB202013791D0 (en) Tidysqueeze 9
GB201918773D0 (en) TidySqueeze 8
GB201913527D0 (en) Nodens 2
GB201910340D0 (en) CAERvest 1
GB201910320D0 (en) Aleck 1
GB201917632D0 (en) Concept 229
GB201915914D0 (en) Concept 227
GB201914147D0 (en) Concept 225
GB201912624D0 (en) Concept 224
GB202115358D0 (en) 13099098001

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018915063

Country of ref document: EP

Effective date: 20200714